Company profile: ADRx
1.1 - Company Overview
Company description
- Provider of a structure-based drug discovery platform that transforms atomic structures into small molecule therapies for protein aggregation diseases, targeting pathological protein structures. Develops small molecule modulators of protein-protein interactions, including amyloids and biomolecular condensates, and advances drug candidates for Alzheimer’s, systemic amyloidosis, ovarian cancer, ALS, and Parkinson’s.
Products and services
- Innovative Drug Discovery Platform: Engineers a structure-guided platform that converts atomic protein architectures into drug-like small molecules targeting Alzheimer’s, ALS, and Parkinson’s neurodegeneration
- Novel Small Molecule Modulators: Produces chemistry-driven modulators that affect pathological protein–protein interactions, including amyloids and biomolecular condensates, enabling targeted interference with disease-associated assemblies
- Therapeutics for Pathological Protein Structures: Architects custom-engineered therapeutics by identifying, designing, and developing products that target patient-derived pathological protein structures implicated in disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ADRx
Cara Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology therapeutics targeting pain and inflammation, including KORSUVA (difelikefalin), an FDA-approved treatment for moderate to severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis, and research and development focused on treating pruritus in Notalgia Paresthetica.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cara Therapeutics company profile →
Burl Concepts
HQ: United States
Website
- Description: Provider of a portable, battery-powered ultrasound device for non-invasive, transcranial brain perfusion assessment and stroke diagnosis. The SONAS system uses microbubble contrast agents to detect cerebral blood perfusion differences.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Burl Concepts company profile →
ElectroCore
HQ: United States
Website
- Description: Provider of neuromodulation therapies for the non-invasive treatment of diseases and disorders, including gammaCore and gammaCore Sapphire devices offering non-invasive vagus nerve stimulation for migraine and cluster headache treatment; Truvaga, a natural solution designed to enhance mental clarity and overall health; and TAC-STIM, a portable device aimed at the military for vagus nerve stimulation with quick administration and long-lasting benefits.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ElectroCore company profile →
Sonoma Bio
HQ: United States
Website
- Description: Provider of Treg and Teff cell therapies and autoimmune disease research, developing adoptive Treg therapies for rheumatoid arthritis, inflammatory bowel disease, and hidradenitis suppurativa. Pipeline includes SBT-77-7101, a Treg cell therapy targeting citrullinated proteins to reduce inflammation, and SBT-11-5301, a Phase 1 effector T cell-modulating biologic, with clinical trials assessing safety and effectiveness.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sonoma Bio company profile →
Saegis Pharma
HQ: United States
Website
- Description: Provider of medicines in development for behavioral disorders, with a pipeline of treatments for central nervous system diseases involving cognitive dysfunction, including Alzheimer’s disease, mild cognitive impairment, and attention deficit hyperactivity disorder.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Saegis Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ADRx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ADRx
2.2 - Growth funds investing in similar companies to ADRx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ADRx
4.2 - Public trading comparable groups for ADRx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →